Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06637501 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia

A Phase 2 study of Chronic Lymphocytic Leukemia, sponsored by BeOne Medicines.

Active
Registry status
Phase 2
Development phase
94
Enrollment target
20
Study locations

NCT06637501 is a Phase 2 study of Chronic Lymphocytic Leukemia that is active but no longer recruiting, run by BeOne Medicines. The registered enrollment target is 94 participants, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06637501, a Phase 2 study of Chronic Lymphocytic Leukemia, is active but no longer recruiting, sponsored by BeOne Medicines.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
94 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax.

Conditions Studied

Chronic Lymphocytic Leukemia

Interventions

  • DRUG Zanubrutinib
  • DRUG Sonrotoclax

Study Locations (20)

Other

  • Centro de Pesquisas Oncologicas Cepon - Florianópolis
  • Hospital de Clinicas de Porto Alegre - Porto AlegreRS
  • Instituto Dor de Pesquisa E Ensino Sao Paulo - São Paulo
  • Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein - São Paulo

Nebraska

  • Nebraska Cancer Specialists (Satellite Site) - Omaha
  • Nebraska Cancer Specialists - Omaha
  • University of Nebraska Medical Center - Omaha

Texas

  • Texas Oncology Dfw - Dallas
  • Texas Oncology Tyler - Tyler

Jiangsu

  • The First Peoples Hospital of Changzhou - Changzhou
  • Jiangsu Province Hospital - Nanjing

Florida

  • Cleveland Clinic Florida - Weston

Georgia

  • Northwest Georgia Oncology Centers Marietta - Marietta

Illinois

  • Illinois Cancer Specialists (Niles) Usor - Niles

Maryland

  • University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore

Trial Details

FieldValue
Enrollment Target 94 participants
Start Date 2024-11-14
Est. Completion 2029-09
Phase Phase 2

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06637501

The ClinicalTrials.gov registry entry for NCT06637501 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 181-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (48% lower). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.

NCT06637501 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Nebraska, Texas.

Frequently Asked Questions

What is clinical trial NCT06637501 about?

NCT06637501 is a clinical study titled "A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia". The purpose of this study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated chronic lymphocytic leukemia (CLL). This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubr...

What is the current status of trial NCT06637501?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2024-11-14. Estimated completion is 2029-09.

What conditions does trial NCT06637501 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia.

What interventions are being tested in trial NCT06637501?

The interventions under investigation include: Zanubrutinib (DRUG), Sonrotoclax (DRUG).

Who is sponsoring clinical trial NCT06637501?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06637501 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Maryland, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.